Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

This study has been terminated.
(Change in Formulation)
Information provided by:
Aeris Therapeutics Identifier:
First received: September 13, 2005
Last updated: February 27, 2008
Last verified: February 2008
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.

Condition Intervention Phase
Pulmonary Emphysema
Biological: BLVR Hydrogel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1/Phase 2 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema

Resource links provided by NLM:

Further study details as provided by Aeris Therapeutics:

Primary Outcome Measures:
  • Product-related life-threatening adverse events, permanently disabling complications and deaths [ Time Frame: 1 year post treatment ]
  • FEV1 [ Time Frame: 12 weeks post treatment ]
  • MRC Dyspnea Score [ Time Frame: 12 weeks post treatment ]
  • Six-Minute Walk Test [ Time Frame: 12 weeks post treatment ]
  • Health-Related Quality of Life [ Time Frame: 12 weeks post treatment ]

Secondary Outcome Measures:
  • Lung function tests [ Time Frame: 12 weeks post treatment ]
  • Lung volume measures [ Time Frame: 12 weeks post treatment ]

Enrollment: 4
Study Start Date: January 2005
Study Completion Date: April 2007
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: single
BLVR treatment
Biological: BLVR Hydrogel
10 mL BLVR Hydrogel

Detailed Description:

Emphysema is a progressive, debilitating disease that affects nearly 3 million people in the United States or roughly one percent of the US population. The disease is characterized by destruction of lung tissue as a result of inflammation caused by exposure to noxious inhaled agents for extended periods. The most common cause of this condition is cigarette smoking, although genetic and occupational causes account for up to 10% of cases. Despite aggressive public health initiatives aimed at discouraging the use of cigarettes, smoking-related lung diseases remain a significant cause of disability and death in the United States. Currently there are 46 million smokers in the US. Due to the number of current and new smokers, emphysema is expected to remain a leading cause of morbidity and mortality in the United States for years to come.

Aeris has developed a novel bronchoscopic system for achieving the benefits of lung volume reduction without surgery. The Bronchoscopic Lung Volume Reduction (BLVR) Hydrogel System, a new investigational therapy for emphysema, is intended to reduce lung volume over a period of weeks by collapsing and promoting the remodeling of diseased areas of the lung. The resulting reduction in lung volume is intended to restore a more normal physiological relationship between lung and chest wall, improve breathing and exercise capacity and alleviate symptoms of chronic dyspnea. The current study will evaluate the safety and efficacy of this procedure in patients with advanced emphysema.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria include:

  • Clinical diagnosis of advanced heterogeneous emphysema
  • Age > 18 years at the time of initial presentation
  • Clinically significant dyspnea (MRC Dyspnea >/= 2)
  • Failure of standard medical therapy to provide relief of symptoms
  • BUN, creatinine, ALT, AST, alkaline phosphatase, WBC, hematocrit, platelet count, PT and PTT within normal limits
  • Pulmonary function tests

Exclusion Criteria:

  • Alpha-1 protease inhibitor deficiency verified by a serum level of < 80 mg% or knowledge of PI*ZZ genotype
  • Body mass index < 15 kg/m2 or > 35 kg/m2
  • Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis
  • Tobacco use within 16 weeks of the initial clinic visit
  • Allergy to fish or pork products or sensitivity to tetracycline
  • FEV1 <20% with DLCO <20% or homogeneous disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00205907

Chaim Sheba (Tel Hashomer) Medical Center
Ramat Gan, Israel, 52621
Sponsors and Collaborators
Aeris Therapeutics
Principal Investigator: Issahar Ben-Dov, MD The Chaim Sheba Medical Center
  More Information

Additional Information:
Responsible Party: Edward P Ingenito, MD, PhD, Medical Director & CSO, Aeris Therapeutics Inc Identifier: NCT00205907     History of Changes
Other Study ID Numbers: C04-003
Study First Received: September 13, 2005
Last Updated: February 27, 2008

Keywords provided by Aeris Therapeutics:
chronic obstructive pulmonary disease
pulmonary emphysema

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases processed this record on April 28, 2017